Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Marginalen Bank regarding a substitution of issuer for its existing capital notes and the issuance of new capital notes
Mandate

Vinge has advised Marginalen Bank regarding a substitution of issuer for its existing capital notes and the issuance of new capital notes

June 03, 2025 Banking and Finance

Vinge has advised Marginalen Bank Bankaktiebolag (publ) regarding a change of issuer for its outstanding capital notes, consisting of SEK 560 million in Tier 2 Capital Notes and SEK 200 million Additional Tier 1 Capital Notes. ESCO Marginalen AB (publ) will assume all obligations under the existing capital notes in connection with the transaction, while Marginalen Bank issues new capital notes in a corresponding amount by way of set-off.

Vinge assisted with the application for approval of the issuer substitution with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen), as well as with obtaining the consent of the noteholders through written procedures and coordination with Nasdaq regarding the continued admission to trading of the existing capital notes on Nasdaq Stockholm.

ABG Sundal Collier acted as the financial advisor for the transaction.

Vinge’s team consisted of Mikael Ståhl, Arvid Weimers, Henrik Schön, Katja Häglund and Julia Gudmundsson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025